You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Enasidenib mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for enasidenib mesylate and what is the scope of patent protection?

Enasidenib mesylate is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Enasidenib mesylate has one hundred and eleven patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for enasidenib mesylate
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for enasidenib mesylate
Generic Entry Date for enasidenib mesylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for enasidenib mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 2
City of Hope Medical CenterPhase 1
National Cancer Institute (NCI)Phase 1

See all enasidenib mesylate clinical trials

Pharmacology for enasidenib mesylate

US Patents and Regulatory Information for enasidenib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bristol Myers Squibb IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Bristol Myers Squibb IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Bristol Myers Squibb IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for enasidenib mesylate

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2010105243 ⤷  Sign Up
Mexico 2014008350 COMPUESTOS TERAPEUTICAMENTE ACTIVOS Y SUS METODOS DE USO. (THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.) ⤷  Sign Up
Australia 2014295938 Therapeutically active compounds and their methods of use ⤷  Sign Up
Mexico 2011009690 MÉTODOS Y COMPOSICIONES PARA TRASTORNOS RELACIONADOS CON LA PROLIFERACIÓN CELURAR. (METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS.) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.